Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 22, 12:39PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ALDX: 9.30 (-1.45), ASMB: 16.78 (-2.76), HEES: 24.98 (-1.82), VLTC: 15.14 (-1.04), REPH: 10.71 (-0.78), ADTN: 16.61 (-1.92), CREE: 32.36 (-3.04)
Tetraphase Pharmaceuticals Appoints Gerri Henwood to Board of Directors
GlobeNewswire - Wed Apr 15, 4:15PM CDT
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the appointment of Gerri Henwood, President and Chief Executive Officer of Recro Pharma, to the Company's Board of Directors. Ms. Henwood brings more than 30 years' experience in product commercialization, clinical development and regulatory approval processes to the Board. She replaces Steven Gullans, co-founder and partner of Excel Venture Fund.
TTPH: 39.96 (-0.50), REPH: 10.71 (-0.78)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 13, 11:44AM CDT
NPD: 2.87 (+0.25), TEAR: 2.39 (+0.08), UQM: 1.02 (-0.02), ASPS: 18.07 (+1.32), CPHR: 11.34 (+0.44), SYRX: 2.09 (-0.05), CHOP: 3.67 (-0.26), NTLS: 5.46 (+0.17), HKTV: 7.67 (-0.33), PME: 1.88 (-0.12), CALI: 1.38 (+0.01), GBSN: 4.98 (+1.44), CTSO: 7.13 (-0.06), ORMP: 7.25 (-0.10), CYTX: 0.96 (-0.09), EXA: 11.49 (+0.01), BAS: 7.88 (+0.07), ENRJ: 1.75 (+0.05), BLDR: 13.00 (-0.09), REPH: 10.71 (-0.78)
Recro Pharma completes acquisition of certain Alkermes assets; Shares rise
Seeking Alpha - at Seeking Alpha - Mon Apr 13, 10:02AM CDT
REPH: 10.71 (-0.78)
Recro Pharma Completes Acquisition of IV/IM Meloxicam and cGMP Manufacturing Facility and Business Unit From Alkermes
GlobeNewswire - Mon Apr 13, 6:00AM CDT
- Transformative Acquisition Diversifies Recro Pharma's Development Risk with Second, Complementary Acute Pain Product
ALKS: 62.60 (-0.24), REPH: 10.71 (-0.78)
Recro Pharma reduces enrollment target in study of lead product candidate; Results expected by mid-year
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 11:26AM CDT
REPH: 10.71 (-0.78)
Recro Pharma Announces Update on On-Going Phase II Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
GlobeNewswire - Thu Apr 09, 6:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post-operative pain today announced that it had completed the prespecified interim analysis conducted on the Company's Phase II, double-blind REC-14-013 trial of Dex-IN in patients who initiate dosing of study medication on Post Op Day 1 following bunionectomy surgery. The purpose of the interim analysis was to allow for a sample size adjustment, if necessary, to maintain the ability to detect a difference in treatment effects between Dex-IN and placebo. The trial was expected to enroll approximately 200-250 patients. As a result of the interim analysis, the total enrollment for the trial was adjusted to approximately 170 patients.
REPH: 10.71 (-0.78)
Can the Rally in Recro Pharma (REPH) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 8:40AM CDT
Can the Rally in Recro Pharma (REPH) Shares Continue?
REPH: 10.71 (-0.78)
Recro Pharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 8:16AM CDT
REPH: 10.71 (-0.78)
Recro Pharma beats by $0.23
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 7:05AM CDT
REPH: 10.71 (-0.78)